Definium Therapeutics Inducement Grants

Definium Therapeutics, a late-stage clinical biopharmaceutical company, announced the issuance of inducement stock options to newly hired non-executive employees. On July 6, 2026, options for 169,740 common shares were granted to eight employees, and on July 20, 2026, options for 30,330 common shares were granted to two employees. The options have exercise prices equal to the closing price on grant dates, vest over four years, and were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4). Definium focuses on developing psychedelic-based treatments for psychiatric and neurological disorders.